Loading data
DRMANasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 2.93 m USD | 8.2 m USD | 4.07 m USD | 5.65 m USD | 3.46 m USD |
| Selling, general and administrative expense | 4.84 m USD | 4.31 m USD | — | — | — |
| Operating profit | -7.77 m USD | -12.51 m USD | -8.04 m USD | -9.67 m USD | -7.86 m USD |
| Income tax expense | — | 0 USD | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -7.56 m USD | -12.29 m USD | -7.79 m USD | -9.61 m USD | -7.9 m USD |
| Net income attributable to common shareholders | — | — | — | -9.61 m USD | -10.46 m USD |
| Basic earnings per share | -8.16 USD/share | -80.32 USD/share | -39.99 USD/share | -13.92 USD/share | -2.43 USD/share |
| Diluted earnings per share | -8.16 USD/share | -80.32 USD/share | -39.99 USD/share | — | — |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.